Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
LOS ANGELES, Oct. 18, 2017 -- Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s shares between November 15, 2016 and August 2, 2017, inclusive (the “Class Period”), are encouraged to contact the firm before October 23, 2017, the lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, click here to participate.
We also encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.goldberglawpc.com/, or by email at [email protected].
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Complaint alleges that throughout the Class Period, Teva issued materially false and/or misleading statements, and/or failed to disclose, that the poor performance of its U.S. generics business resulted in the Company recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva’s dividend by 75%. When this news was announced, Teva’s stock price fell materially, which caused investors harm.
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Contact:
Goldberg Law PC, Los Angeles
Michael Goldberg, Esq., 800-977-7401
Brian Schall, Esq., 800-977-7401
[email protected]
www.Goldberglawpc.com
